Pacira Biosciences Inc - PCRX STOCK NEWS

Pacira BioSciences reported preliminary net product sales of $57.5 million for November 2022, a slight decrease from the previous year. EXPAREL sales were $46.0 million, nearly flat compared to $46.5 million in November 2021, with unit volumes increasing by 4%. The company has initiated programs to improve access to EXPAREL, including 340B pricing, which targets 5,200 new accounts. ZILRETTA and iovera° generated $10.0 million and $1.5 million in sales, respectively. The ongoing impacts of COVID-19 are still affecting the elective surgery market, leading to no guidance for 2022 revenue.

On November 17, 2022, a national survey revealed that nearly one in four U.S. adults suffer from chronic knee pain, significantly impacting their daily lives. Conducted by Wakefield Research for Pacira, the survey found that 97% of participants reported negative effects on their daily activities, with many unable to climb stairs or exercise. Notably, 91% missed social events due to pain, and 45% used opioids for management. Concerns about total knee replacement surgery were high, with 88% of patients worried about associated pain and recovery. Innovative non-opioid treatments like iovera° offer promising alternatives.

Pacira BioSciences (Nasdaq: PCRX) reported preliminary net product sales of $54.9 million for October 2022, driven by continued growth in EXPAREL, ZILRETTA, and iovera° sales. EXPAREL net sales reached $45.0 million, up from $42.5 million in October 2021, with average daily sales increasing by 106%. Despite recent challenges from COVID-19 affecting elective surgeries, the company maintains confidence for double-digit growth and plans for new market expansions. No 2022 revenue guidance was provided due to ongoing uncertainties.

Pacira BioSciences, Inc. (NASDAQ: PCRX) announced participation in upcoming healthcare conferences. The company will engage in an analyst-led fireside chat at the Jefferies London Healthcare Conference on November 15 at 8:00 AM GMT and the 34th Annual Piper Sandler Healthcare Conference on November 29 at 2:30 PM ET. Live audio can be accessed on their website, with replays available for two weeks post-event. Pacira is dedicated to offering non-opioid pain management options and has three commercial products for pain relief.

Pacira BioSciences reported a 31% increase in revenue to $167.5 million for Q3 2022, with net product sales of $132.6 million for EXPAREL. The company experienced a net loss of $0.7 million or $(0.02) per share, contrasting with a profit in Q3 2021. Adjusted EBITDA rose to $55.2 million, up from $48.1 million a year prior. Notably, the company received a new patent for EXPAREL, extending exclusivity until 2041, and reported positive results from Phase 3 studies, enhancing its product portfolio and potential revenue streams.

Pacira BioSciences, Inc. (NASDAQ:PCRX) will release its third quarter financial results on November 3, 2022, before U.S. markets open. A live conference call will follow at 8:30 a.m. ET, allowing participants to engage in a Q&A session. Pre-registration for telephone participation is required. The company, known for its non-opioid pain management solutions, aims to redefine opioid use and has three commercial-stage products: EXPAREL, ZILRETTA, and iovera. A webcast of the call will be available for those unable to attend live.

Pacira BioSciences (PCRX) reported preliminary revenues of $167.5 million for Q3 2022, a significant increase from $127.7 million in Q3 2021. EXPAREL sales reached $132.6 million for Q3 2022, showing a 109% increase year-over-year. In September, daily sales rose 113% compared to the previous year. The company remains optimistic about revenue growth despite ongoing challenges from COVID-19 and the elective surgery market. No guidance for 2022 revenue or gross margin is provided due to ongoing uncertainties.

Pacira BioSciences (Nasdaq: PCRX) has partnered with Sevāredent Sourcing Solutions to enhance access to EXPAREL (bupivacaine liposome injectable suspension) for pain management in oral and maxillofacial surgeries. This initiative will benefit over 1,800 dental offices across the U.S. by providing comprehensive training and support to reduce opioid exposure. The collaboration aims to improve patient outcomes and align with the growing demand for non-opioid alternatives amid the opioid crisis.

Pacira BioSciences (PCRX) announced positive topline results from its Phase 3 study of EXPAREL for postsurgical pain management in bunionectomy patients. The study demonstrated a statistically significant reduction in pain scores and opioid consumption compared to bupivacaine HCl, meeting both primary and secondary endpoints (p<0.00001). The company plans to submit a supplemental New Drug Application early in 2023 to expand EXPAREL's label for new indications. The results position EXPAREL as a groundbreaking option for regional analgesia, aiming to enhance patient outcomes while minimizing opioid use.